Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development expenses	$ 16,994,828	$ 5,888,004
Research and development expenses - intellectual property acquired	21,325,527	13,250,000
General and administrative expenses	18,384,545	7,294,764
Intangible asset impairment	2,351,988	0
Total operating expenses	59,056,888	26,432,768
Loss from operations	(59,056,888)	(26,432,768)
Other income (expenses):
Interest expense	(11,235)	(5,840,614)
Interest income	1,173	484
Gain on settlement	0	211,430
Gain (loss) on debt extinguishment	0	(609,998)
Change in fair value of liability	532,353	0
Other income	(3,252)	0
Total other income (expense)	519,039	(6,238,698)
Net loss	(58,537,849)	(32,671,466)
Other comprehensive loss:
Foreign currency translation adjustment	(111,589)	(154,009)
Total comprehensive loss	(58,649,438)	(32,825,475)
Net loss	(58,537,849)	(32,671,466)
Deemed dividend on preferred stock	(4,507,125)	(8,155,212)
Deemed dividend on preferred stock exchanges	(21,008,253)	0
Preferred stock dividends	(465,361)	(905,660)
Net loss applicable to common stockholders	$ (84,518,588)	$ (41,732,338)
Basic weighted average shares outstanding (in shares)	8,925,728	2,843,629
Diluted weighted average shares outstanding (in shares)	8,925,728	2,843,629
Loss per share applicable to common shareholders - basic (in dollars per share)	$ (9.47)	$ (14.68)
Loss per share applicable to common shareholders - diluted (in dollars per share)	$ (9.47)	$ (14.68)